🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

203 results for “Novartis” Clear

  1. IPTACOPAN

    Novartis Ophthalmics Europe

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  2. IPTACOPAN HYDROCHLORIDE

    Novartis Ophthalmics Europe

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  3. IPTACOPAN, LNP023

    Novartis Ophthalmics Europe

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  4. Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen

    Novartis Ophthalmics Europe

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  5. LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, ANASTROZOLE, GOSERELIN, LETROZOLE, GOSERELIN, EXEMESTANE, RIBOCICLIB

    Novartis Ophthalmics Europe

    HR-positive HER-2- negative Breast Cancer

    phase 3 small molecule active

    1 trial

  6. LOU064

    Novartis Ophthalmics Europe

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  7. LOU064, CLINDAMYCIN , Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, LOU064, Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , -

    Novartis Ophthalmics Europe

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  8. LOU064, COLESTYRAMINE , TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, MEDICINAL CHARCOAL

    Novartis Ophthalmics Europe

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  9. LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, -, -

    Novartis Ophthalmics Europe

    Chronic Inducible Urticaria (CINDU)

    phase 3 small molecule active

    1 trial

  10. LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE , Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, TERIFLUNOMIDE, MEDICINAL CHARCOAL

    Novartis Ophthalmics Europe

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  11. Locametz 25 micrograms kit for radiopharmaceutical preparation, ABIRATERONE , LEUPRORELIN , HISTRELIN , ENZALUTAMIDE , TRIPTORELIN , NILUTAMIDE , Pluvicto 1 000 MBq/mL solution for injection/infusion, GOSERELIN , DEGARELIX , BICALUTAMIDE , BUSERELIN , -, RELUGOLIX , APALUTAMIDE , DAROLUTAMIDE , FLUTAMIDE

    Novartis Ophthalmics Europe

    PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  12. Locametz 25 micrograms kit for radiopharmaceutical preparation, PIFLUFOLASTAT (18F), PIFLUFOLASTAT (18F), Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Ophthalmics Europe

    Oligometastatic prostate cancer (OMPC)

    phase 3 small molecule active

    1 trial

  13. METOCLOPRAMIDE , -, SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion, OCTREOTIDE

    Novartis Ophthalmics Europe

    Gastroenteropancreatic neuroendocrine tumor (GEP-NET)

    phase 3 small molecule active

    1 trial

  14. MYCOPHENOLIC ACID, -, MYCOPHENOLATE MOFETIL, VAY736, TENOFOVIR ALAFENAMIDE , ENTECAVIR , TENOFOVIR DISOPROXIL

    Novartis Ophthalmics Europe

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  15. MYCOPHENOLIC ACID, TENOFOVIR ALAFENAMIDE , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe , Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, VAY736, ENTECAVIR , -, TENOFOVIR DISOPROXIL , VAY736, MYCOPHENOLATE MOFETIL

    Novartis Ophthalmics Europe

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  16. NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB

    Novartis Ophthalmics Europe

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  17. NIO752, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung

    Novartis Ophthalmics Europe

    Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

    phase 3 small molecule active

    1 trial

  18. OAV101B, Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Ophthalmics Europe

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  19. OCRELIZUMAB, LOU064, OCRELIZUMAB

    Novartis Ophthalmics Europe

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  20. PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB

    Novartis Ophthalmics Europe

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  21. PREDNISONE, Placebo to AIN457 150mg/1mL solution for injection in pre-filled syringe, SECUKINUMAB, PREDNISONE, Placebo to Prednisone 1 mg, 2.5mg, 5mg, 20mg hard gelatin capsule with tablet content, PREDNISONE, PREDNISONE, SECUKINUMAB, Placebo to AIN457 300mg/2mL solution for injection in pre-filled syringe

    Novartis Ophthalmics Europe

    Giant cell arteritis (GCA)

    phase 3 small molecule active

    1 trial

  22. Placebo - Film coated tablet for oral use, atrasentan

    Novartis Ophthalmics Europe

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  23. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023 200 mg), IPTACOPAN

    Novartis Ophthalmics Europe

    IgA Nephropathy

    phase 3 small molecule active

    1 trial

  24. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023), IPTACOPAN

    Novartis Ophthalmics Europe

    generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources